-
September 20, 2016PREVIEW
Abaloparatide, an investigational peptide that selectively activates the parathyroid hormone (PTH)–type 1 receptor, reduced the risk of new vertebral and nonvertebral fractures and increased bone...
-
August 23, 2016PREVIEW
Long-term use of alendronate, including more than 10 years of continuous use, was not associated with an increased risk of subtrochanteric femur and femoral shaft (ST/FS) fractures and was...
-
August 16, 2016PREVIEW
Addition of liraglutide (Victoza—Novo Nordisk) to standard of care therapy in patients with type 2 diabetes at high risk for cardiovascular (CV) events resulted in a reduced risk of adverse CV...
-
June 28, 2016PREVIEW
The risk of hypoglycemia increases substantially when a dipeptidyl peptidase-4 (DPP-4) inhibitor is given with a sulfonylurea, emphasizing the need to reduce the sulfonylurea dose and educate...
-
June 14, 2016PREVIEW
Long-term exposure of testosterone replacement therapy was associated with a lower risk of death, cardiovascular (CV) events, and prostate cancer, whereas shorter durations of therapy increased...
Pages
